Biogen, Eisai halt work on second of 3 clinical-stage Alzheimer's drugs

Cambridge drug giant Biogen’s mission to find what has been called the pharmaceutical industry’s “holy grail” — a treatment for the memory deteriorating condition Alzheimer’s disease — has hit another dead-end.Biogen (Nasdaq: BIIB) and its development partner Eisai Inc. announced Friday they have halted work on one of their remaining treatments, elenbecestat, due to what they said is a poor risk-benefit outlook.Elenbecestat was one of three drugs Biogen